Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.

Matsui S, Simon R, Qu P, Shaughnessy JD Jr, Barlogie B, Crowley J.

Clin Cancer Res. 2012 Nov 1;18(21):6065-73. doi: 10.1158/1078-0432.CCR-12-1206. Epub 2012 Aug 27.

2.

Roadmap for developing and validating therapeutically relevant genomic classifiers.

Simon R.

J Clin Oncol. 2005 Oct 10;23(29):7332-41. Epub 2005 Sep 6. Review.

PMID:
16145063
3.

Genomic biomarkers for personalized medicine: development and validation in clinical studies.

Matsui S.

Comput Math Methods Med. 2013;2013:865980. doi: 10.1155/2013/865980. Epub 2013 Apr 17. Review.

4.

Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice.

Michiels S, Ternès N, Rotolo F.

Ann Oncol. 2016 Dec;27(12):2160-2167. doi: 10.1093/annonc/mdw307. Epub 2016 Sep 15. Review.

5.

Critical review of microarray-based prognostic tests and trials in breast cancer.

Koscielny S.

Curr Opin Obstet Gynecol. 2008 Feb;20(1):47-50. doi: 10.1097/GCO.0b013e3282f39d9e. Review.

PMID:
18197005
6.

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Albain KS, Paik S, van't Veer L.

Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5. Review.

PMID:
19914534
7.

Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials.

Burczynski ME, Oestreicher JL, Cahilly MJ, Mounts DP, Whitley MZ, Speicher LA, Trepicchio WL.

Curr Mol Med. 2005 Feb;5(1):83-102. Review.

PMID:
15720272
8.
9.

Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data.

Wang E, Zaman N, Mcgee S, Milanese JS, Masoudi-Nejad A, O'Connor-McCourt M.

Semin Cancer Biol. 2015 Feb;30:4-12. doi: 10.1016/j.semcancer.2014.04.002. Epub 2014 Apr 18. Review.

PMID:
24747696
10.

Omics-based clinical trial designs.

Buyse M, Michiels S.

Curr Opin Oncol. 2013 May;25(3):289-95. doi: 10.1097/CCO.0b013e32835ff2fe. Review.

PMID:
23475192
11.

Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

Subramanian J, Simon R.

J Natl Cancer Inst. 2010 Apr 7;102(7):464-74. doi: 10.1093/jnci/djq025. Epub 2010 Mar 16. Review.

12.

Impact of gene expression profiling tests on breast cancer outcomes.

Marchionni L, Wilson RF, Marinopoulos SS, Wolff AC, Parmigiani G, Bass EB, Goodman SN.

Evid Rep Technol Assess (Full Rep). 2007 Dec;(160):1-105. Review.

13.

"Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.

Glinsky GV.

J Clin Oncol. 2008 Jun 10;26(17):2846-53. doi: 10.1200/JCO.2008.17.0266. Review.

PMID:
18539963
14.

State of the science: molecular classifications of breast cancer for clinical diagnostics.

Robison JE, Perreard L, Bernard PS.

Clin Biochem. 2004 Jul;37(7):572-8. Review.

PMID:
15234238
15.

Genomic signatures for individualized treatment of malignant tumors.

Kunz M.

Curr Drug Discov Technol. 2008 Mar;5(1):9-14. Review.

PMID:
18537562
16.

The importance of identifying and validating prognostic factors in oncology.

Halabi S, Owzar K.

Semin Oncol. 2010 Apr;37(2):e9-18. doi: 10.1053/j.seminoncol.2010.04.001. Review.

17.
18.

Do predictive signatures really predict response to cancer chemotherapy?

Borst P, Wessels L.

Cell Cycle. 2010 Dec 15;9(24):4836-40. Epub 2010 Dec 15. Review.

PMID:
21150277
19.

Gene-expression signatures in oncology diagnostics.

Mazumder A, Wang Y.

Pharmacogenomics. 2006 Dec;7(8):1167-73. Review.

PMID:
17184204
20.

Drug-diagnostics co-development in oncology.

Simon R.

Front Oncol. 2013 Dec 23;3:315. doi: 10.3389/fonc.2013.00315. Review.

Supplemental Content

Support Center